User profiles for "author:Lucia Tricarico"
 | Lucia TricaricoCardiology department, Università degli studi di Foggia Verified email at unifg.it Cited by 417 |
Liver disease and heart failure: Back and forth
In their clinical practice, physicians can face heart diseases (chronic or acute heart failure)
affecting the liver and liver diseases affecting the heart. Systemic diseases can also affect …
affecting the liver and liver diseases affecting the heart. Systemic diseases can also affect …
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine
monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure …
monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure …
[HTML][HTML] Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets
M Correale, L Tricarico, F Croella, S Alfieri… - Frontiers in …, 2023 - frontiersin.org
Despite recent advances in chronic heart failure (HF) management, the prognosis of HF
patients is poor. This highlights the need for researching new drugs targeting, beyond …
patients is poor. This highlights the need for researching new drugs targeting, beyond …
[HTML][HTML] Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry
Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …
Network meta‐analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction
V De Marzo, G Savarese, L Tricarico… - Journal of internal …, 2022 - Wiley Online Library
Background Following the availability of new drugs for chronic heart failure (HF) with
reduced ejection fraction (HFrEF), we sought to provide an updated and comparative …
reduced ejection fraction (HFrEF), we sought to provide an updated and comparative …
[HTML][HTML] Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure
M Correale, P Mazzeo, A Mallardi, A Leopizzi… - … Drugs and Therapy, 2022 - Springer
Purpose The use of sodium-glucose-cotransporter-type-2 inhibitors (SGLT2i) was
associated in previous studies with an improved vascular function in non-human …
associated in previous studies with an improved vascular function in non-human …
Electrocardiographic findings and mortality in covid-19 patients hospitalized in different clinical settings
M Mele, L Tricarico, E Vitale, A Favia, F Croella… - Heart & Lung, 2022 - Elsevier
Background Twelve-lead electrocardiogram (ECG) represents the first-line approach for
cardiovascular assessment in patients with Covid-19. Objectives We sought to describe and …
cardiovascular assessment in patients with Covid-19. Objectives We sought to describe and …
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a …
P Ameri, V De Marzo, GB Zoccai… - European Heart …, 2022 - academic.oup.com
Aims We assessed the efficacy of the drugs developed after neurohormonal inhibition
(NEUi) in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and …
(NEUi) in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and …
[HTML][HTML] Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches
Abstract The recent Sars-Cov-2 pandemic (COVID-19) has led to growing research on the
relationship between thromboembolism and Sars-Cov-2 infection. Nowadays, endothelial …
relationship between thromboembolism and Sars-Cov-2 infection. Nowadays, endothelial …
[HTML][HTML] New targets in heart failure drug therapy
M Correale, L Tricarico, M Fortunato… - Frontiers in …, 2021 - frontiersin.org
Despite recent advances in chronic heart failure management (either pharmacological or
non-pharmacological), the prognosis of heart failure (HF) patients remains poor. This poor …
non-pharmacological), the prognosis of heart failure (HF) patients remains poor. This poor …